



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

## Dengue Tetravalent Vaccine (Live, Attenuated) Takeda

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
WS/2809	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>SmPC new text</p> <p>In this worksharing procedure, the list of adverse</p>	17/07/2025		SmPC and PL	<p>SmPC new text</p> <p>In this worksharing procedure, the list of adverse reactions in the SmPC has been updated to add 'eye pain' with frequency uncommon based on available post-marketing data. Based on biological plausibility and a plausible time to onset reported in the post marketing cases, eye pain</p>

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	<p>reactions in the SmPC has been updated to add 'eye pain' with frequency uncommon based on available post-marketing data. Based on biological plausibility and a plausible time to onset reported in the post marketing cases, eye pain occurrence on cases of vaccine-induced viremia cannot be excluded. In addition, the MAH proposed editorial amendments in section 4.3 and 4.5 of the SmPC to clarify the use of immunosuppressants prior to vaccination with TDV. Nevertheless, the timing to avoid vaccination after the immunosuppressive treatment (other than glucocosteroids) is to be considered on an individual basis. The Package leaflet has been updated accordingly.</p> <p>For more information, please refer to the Summary of Product Characteristics.</p> <p>SmPC new text</p> <p>In this worksharing procedure, the list of adverse reactions in the SmPC has been updated to add 'eye pain' with frequency uncommon based on available post-marketing data. Based on biological plausibility and a plausible time to onset reported in the post marketing cases, eye pain occurrence on cases of vaccine-induced viremia cannot be excluded. In addition, the MAH proposed editorial amendments in section 4.3 and 4.5 of the SmPC to clarify the use of immunosuppressants prior to vaccination with TDV. Nevertheless, the timing to avoid vaccination after the immunosuppressive treatment (other than glucocosteroids) is to be considered on an individual basis. The Package leaflet has been updated accordingly.</p>				<p>occurrence on cases of vaccine-induced viremia cannot be excluded. In addition, the MAH proposed editorial amendments in section 4.3 and 4.5 of the SmPC to clarify the use of immunosuppressants prior to vaccination with TDV. Nevertheless, the timing to avoid vaccination after the immunosuppressive treatment (other than glucocosteroids) is to be considered on an individual basis. The Package leaflet has been updated accordingly.</p> <p>For more information, please refer to the Summary of Product Characteristics.</p>
--	--	--	--	--	---

	<p>For more information, please refer to the Summary of Product Characteristics.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>				
PSUV/0019	Periodic Safety Update	27/03/2025	n/a		Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUV/0019.
WS/2777/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> <p>B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method</p>	16/01/2025	n/a		

	B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold				
WS/2742/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS</p>	31/10/2024	n/a		
WS/2695	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	31/10/2024	31/10/2024	SmPC and PL	
WS/2750	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.f.1.b.5 - Stability of FP - Extension of the shelf</p>	03/10/2024	03/10/2024	SmPC	

	life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol				
PSUV/0014	Periodic Safety Update	03/10/2024	n/a		PRAC Recommendation - maintenance
WS/2593	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	05/09/2024		SmPC and PL	For more information, please refer to the Summary of Product Characteristics.
IG/1766	B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR	01/08/2024	n/a		
WS/2618	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)</p>	18/04/2024	n/a		
PSUV/0011	Periodic Safety Update	21/03/2024	n/a		Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUV/0011.
WS/2575	This was an application for a variation following a	14/12/2023	n/a		

	<p>worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p>				
IG/1669/G	<p>This was an application for a group of variations.</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p>	25/10/2023	n/a		
WS/2522/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a</p>	19/10/2023	n/a		

	biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate				
PSUV/0004	Periodic Safety Update	28/09/2023	n/a		PRAC Recommendation - maintenance
IB/0008	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	09/08/2023	n/a		
IB/0006	B.II.f.1.e - Stability of FP - Change to an approved stability protocol	06/07/2023	n/a		
IB/0005/G	This was an application for a group of variations.  B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)  B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	23/06/2023	n/a		

IB/0003	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	03/05/2023	n/a		
IB/0002/G	<p>This was an application for a group of variations.</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p>	12/04/2023	n/a		
IB/0001/G	<p>This was an application for a group of variations.</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size</p>	15/03/2023	n/a		



